Free Helpline
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Learn about the IHC test, a crucial diagnostic tool for identifying HER2-positive breast cancer and guiding treatment decisions. Understand the procedure, results, and importance of accurate diagnosis.
Breast cancer is a significant health concern, particularly for individuals assigned female at birth. It stands as the most common cancer diagnosed in this group, accounting for approximately 30 percent of all new cases annually, as per the American Cancer Society. While breast cancer encompasses various types, a crucial classification involves the presence of HER2 protein. Some breast cancers are identified as HER2-positive. This designation means that the cancer cells exhibit elevated levels of the HER2 protein (human epidermal growth factor receptor 2) on their surface. This protein plays a role in cell growth, and its overexpression can lead to faster cancer progression. Between 2012 and 2016, about 15 percent of all breast cancers were found to be HER2-positive.
The IHC test, which stands for Immunohistochemistry, is a vital diagnostic tool used to determine if a breast cancer is HER2-positive. This test is performed on a sample of breast tissue obtained through a biopsy or surgical procedure, such as a lumpectomy or mastectomy. The core principle of the IHC test involves using antibodies that are specifically designed to bind to the HER2 protein. When these antibodies are applied to the tissue sample, they will attach to any HER2 protein present on the cancer cells. Subsequently, a special chemical is introduced, which causes a visible color change in the areas where the HER2 protein is detected. The intensity of this color change is then used to report the results, indicating the level of HER2 protein present.
The IHC test is instrumental in assessing the amount of HER2 protein on the surface of cancer cells. This information is critical for several reasons. When you are diagnosed with breast cancer, understanding its stage, along with your hormone receptor status and HER2 status, is paramount. This comprehensive data guides your medical team in selecting the most effective treatment plan. For HER2-positive breast cancers, specific targeted therapy drugs are available that can effectively block the activity of the HER2 protein, thereby inhibiting cancer growth. Examples of such targeted therapies include trastuzumab (Herceptin) and ado-trastuzumab emtansine (Kadcyla).
An IHC test is typically performed on a tissue sample collected via a breast biopsy. Doctors often utilize imaging technologies, such as ultrasound or mammography, to precisely guide a thin, hollow needle to the suspicious area to obtain the tissue sample. Before the procedure, a local anesthetic is administered to numb the area, ensuring minimal discomfort. While you might experience some pressure or a pulling sensation during the biopsy, you should not feel pain. A breast biopsy is an outpatient procedure, meaning you can return home the same day. The collected tissue sample is then sent to a pathologist, a medical doctor specializing in the analysis of tissues, for the IHC testing.
The interpretation of IHC test results is based on the observed color change in the tissue sample after the staining process. However, it's important to note that different laboratories or pathologists might have slight variations in how they interpret these color changes. This variability, along with other factors, means that an IHC test can sometimes yield equivocal (unclear) results. In such cases, or when there's a need for further confirmation, a more advanced and often more expensive test called a FISH (Fluorescence In Situ Hybridization) test may be recommended. The FISH test provides a more definitive assessment of HER2 gene amplification.
While the IHC test is a valuable initial screening tool, there is a possibility of inaccurate results, particularly if the findings are equivocal. Receiving an incorrect IHC result can have significant implications for your breast cancer treatment. For instance, a false-positive result might lead to the administration of targeted therapy drugs that are not effective for your specific type of cancer, potentially exposing you to unnecessary side effects without therapeutic benefit. Conversely, a false-negative result could mean that you miss out on crucial targeted therapies that could significantly improve your outcome. This is why, in cases of equivocal results or when a high degree of certainty is required, a FISH test is often employed as a confirmatory diagnostic step. Your doctor will discuss the best course of action based on your individual situation and the results of your tests.
It is essential to consult your doctor if you notice any changes in your breasts, such as a lump, skin dimpling, nipple discharge, or changes in breast shape or size. Early detection is key in managing breast cancer effectively. If you have been diagnosed with breast cancer, your doctor will explain the results of your tests, including the IHC test, and discuss the implications for your treatment plan. Do not hesitate to ask questions and seek clarification regarding your diagnosis and treatment options.
The main purpose of the IHC test is to determine if breast cancer cells are HER2-positive, meaning they have high levels of HER2 protein on their surface, which can influence treatment decisions.
A local anesthetic is used during the biopsy procedure for the IHC test, so you should not feel pain. You might experience some pressure or discomfort.
Typically, it takes a few days to a week after the biopsy for the IHC test results to be available and for your doctor to contact you.
If the IHC test result is equivocal (unclear), your doctor may recommend a follow-up FISH test for a more definitive diagnosis.
Yes, like any diagnostic test, the IHC test can sometimes produce inaccurate results, such as false-positive or false-negative findings. This is why confirmatory tests like FISH are sometimes used.
This section adds practical context and preventive advice to help readers make informed healthcare decisions. It is important to verify symptoms early, consult qualified doctors, and avoid self-medication for persistent health issues.
Maintaining healthy routines, following prescribed treatment plans, and attending regular checkups can improve outcomes. If symptoms worsen or red-flag signs appear, immediate medical evaluation is recommended.
Track symptoms and duration.
Follow diagnosis and treatment from a licensed practitioner.
Review medication side effects with your doctor.
Seek urgent care for severe warning signs.
Learn about potential side effects of CML treatments like TKIs, interferon, chemotherapy, and stem cell transplants. Understand what to expect and how to communicate with your doctor for effective management.
April 1, 2026
Discover essential support resources, financial aid options, and community connections for individuals navigating life with Chronic Myeloid Leukemia (CML). Find practical advice and empathetic guidance.
April 1, 2026
Explore targeted therapy for multiple myeloma. Learn how these precision treatments work, their types, potential side effects, and how they're used alongside other therapies to manage this blood cancer.
April 1, 2026